Incidence of thrombosis in relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel: Mayo Clinic experience

Chimeric antigen receptor (CAR) T-cell therapy is effective in relapsed/refractory large B-cell lymphoma and results in a unique toxicity profile, namely cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome. The hyper-inflammatory state associated with these toxicities has been suggested to increase the risk of thrombosis.
We conducted a retrospective analysis of patients treated with axicabtagene ciloleucel (axi-cel) to assess the rate of thrombosis with axi-cel therapy from the time of CAR T-cell infusion until the end of hospitalization, when performed in the inpatient setting, or up to day +30 when performed in the outpatient setting. Ninety-two (95%) of 97 patients were hospitalized during axi-cel therapy and 85 (88%) developed CRS. Fifty-five patients (57%) received concurrent anticoagulation (53 as prophylaxis). Patients with prior VTE did not have progression https://joplink.net/antigens/ or evidence of new VTE. Only 2 (2.1%) patients developed VTE. These results demonstrate a low-risk for thrombosis in axi-cel recipients.

The Protective Action of Piperlongumine Against Mycobacterial Pulmonary Tuberculosis in Its Mitigation of Inflammation and Macrophage Infiltration in Male BALB/c Mice

Introduction: Piperlongumine (PL) is a bioactive alkaloid and medicinal compound of piperamide isolated from the long pepper (Piper longum Linn). It has demonstrated bactericidal action against Mycobacterium tuberculosis (MTB), the cause of pulmonary tuberculosis; nevertheless, immunomodulatory activity had not been identified for it in MTB-triggered granulomatous inflammation. This study investigated if piperlongumine could inhibit such inflammation.
Material and methods: Mycobacterium tuberculosis strain H37Rv was subjected to a broth microdilution assay. Piperlongumine at 5, 15, and 25 μg/mL, 0.2% dimethyl sulphoxide as control or 4 μM of dexamethasone were tested in vitro on MH-S murine alveolar macrophages. BALB/c mice were orally administered PL at 50, 100 and 150 mg/kg b.w. after trehalose-6,6-dimycolate (TDM) stimulation.
Chemokine and cytokine concentrations were determined in lung supernatants. Flow cytometry and Western blot analysis were performed to determine phosphorylated spleen tyrosine kinase (Syk), c-Jun N-terminal kinase (JNK) and extracellular signal-regulated kinase (ERK) pathways.
Results: Piperlongumine inhibited inflammatory mediators and adherence of lymphocyte function-associated antigen 1 to MH-S cells following TDM activation. It also improved macrophage clearance of MTB. In TDM-stimulated MH-S cells, PL significantly influenced the macrophage inducible Ca2+-dependent lectin receptor (Mincle)-Syk-ERK signalling pathway. Oral dosing of PL effectively suppressed the development of pulmonary granulomas and inflammatory reactions in the TDM-elicited mouse granuloma model.

Prevalence of Toxoplasma Gondii in Retail Fresh Meat Products from Free-range Chickens in Spain

Toxoplasma gondii is one of the most prevalent zoonotic protozoan parasites worldwide and affects the vast majority of warm-blooded animal species, including humans. Postnatal infection in humans occurs through the ingestion of sporulated T. gondii oocysts or via the oral intake of parasite tissue cysts during the consumption of raw or undercooked meat. In this regard, given their high exposure to oocysts, chickens (Gallus domesticus) raised on the ground constitute a potential source of T. gondii.
Material and methods: For the first time in Spain, a survey was undertaken in commercial retail free-range poultry. A total of 50 thighs from different animals were analysed. The samples were homogenised and an acid pepsin digestion procedure was applied prior to molecular analysis. Toxoplasma gondii DNA was isolated from meat by qPCR. Two sets of primers were used for DNA amplification targeting the specific sequence of a 529 bp repeat element and another set of primers was utilised for the surface antigen protein-1 gene.

Interrelationships between amphiregulin, kisspeptin, FSH and FSH receptor in promotion of human ovarian cell functions

The aim of this study was to investigate: (1) the ability of granulosa cells to produce amphiregulin (AREG), kisspeptin (KISS) and FSH receptor (FSHR); (2) the role of AREG and KISS in the control of ovarian functions; (3) the effect of FSH and KISS on AREG; and (4) the ability of KISS to affect FSHR and to modify FSH action on AREG output by human ovarian granulosa cells. We examined: (1) time-dependent accumulation of AREG; (2) effects of AREG (0, 1, 10, 100ng/mL) and KISS (0, 1, 10, 100ng/mL) on granulosa cell functions; and (3) the effects of KISS (0, 1, 10, 100ng/mL), FSH (0, 1, 10, 100ng/mL), and their combinations on AREG release.
Viability, markers of proliferation [accumulation ofproliferating cell nuclear antigen (PCNA) cyclin B1 and sodium 3′-[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis(4-methoxy6-nitro)benzene sulfonic acid hydrate (XTT formazan)] and apoptosis (accumulation of bax, caspase 3 and terminal deoxynucleotidyl transferase dUTP nick-end labelling), accumulation of KISS, FSHR and steroid hormones, and AREG release were analysed by Trypan blue exclusion test, quantitative immunocytochemistry, XTT, terminal deoxynucleotidyl transferase dUTP nick-end labelling assays and enzyme-linked immunosorbent assay.
AREG promoted cell viability, proliferation and steroid hormone output, and inhibited apoptosis. KISS (1 and 10ng/mL) stimulated viability, proliferation, steroid hormone release and occurrence of FSHR and suppressed apoptosis and AREG output; KISS (100ng/mL) had the opposite effect. FSH stimulated AREG release, whilst addition of KISS reversed this FSH effect. FSH mimicked and promoted the inhibitory effect of KISS on AREG release. These results suggest an intra-ovarian production and a functional interrelationship between AREG, KISS, FSH and FSHR in direct regulation of basic ovarian cell functions.

Novel PE and APC tandems: Additional near-infrared fluorochromes for use in spectral flow cytometry

Recent advances in flow cytometry instrumentation and fluorochrome chemistries have greatly increased fluorescent conjugated antibody combinations that can be used reliably and easily in routine experiments. The Cytek Aurora flow cytometer was first released with three excitation lasers (405, 488, and 640 nm) and incorporated the latest Avalanche Photodiode (APD) technology, demonstrating significant improvement in sensitivity for fluorescent emission signals longer than 800 nm.
However, there are limited commercially available fluorochromes capable of excitation with peak emission signals beyond 800 nm. To address this gap, we engineered six new fluorochromes: PE-750, PE-800, PE-830 for the 488 nm laser and APC-750, APC-800, APC-830 for the 640 nm laser.
Utilizing the principal of fluorescence resonance energy transfer (FRET), these novel structures were created by covalently linking a protein donor dye with an organic small molecule acceptor dye. Additionally, each of these fluorochrome conjugates were shown to be compatible with fixation/permeabilization buffer reagents, and demonstrated acceptable brightness and stability when conjugated to antigen-specific monoclonal antibodies. These six novel fluorochrome reagents can increase the numbers of fluorochromes that can be used on a spectral flow cytometer.

Paraneoplastic and Other Autoimmune Encephalitides: Antineuronal Antibodies, T Lymphocytes, and Questions of Pathogenesis

Autoimmune and paraneoplastic encephalitides represent an increasingly recognized cause of devastating human illness as well as an emerging area of neurological injury associated with immune checkpoint inhibitors. Two groups of antibodies have been detected in affected patients. Antibodies in the first group are directed against neuronal cell surface membrane proteins and are exemplified by antibodies directed against the N-methyl-D-aspartate receptor (anti-NMDAR), found in patients with autoimmune encephalitis, and antibodies directed against the leucine-rich glioma-inactivated 1 protein (anti-LGI1), associated with faciobrachial dystonic seizures and limbic encephalitis. Antibodies in this group produce non-lethal neuronal dysfunction, and their associated conditions often respond to treatment.
  • Antibodies in the second group, as exemplified by anti-Yo antibody, found in patients with rapidly progressive cerebellar syndrome, and anti-Hu antibody, associated with encephalomyelitis, react with intracellular neuronal antigens.
  • These antibodies are characteristically found in patients with underlying malignancy, and neurological impairment is the result of neuronal death. Within the last few years, major advances have been made in understanding the pathogenesis of neurological disorders associated with antibodies against neuronal cell surface antigens.
  • In contrast, the events that lead to neuronal death in conditions associated with antibodies directed against intracellular antigens, such as anti-Yo and anti-Hu, remain poorly understood, and the respective roles of antibodies and T lymphocytes in causing neuronal injury have not been defined in an animal model.
  • In this review, we discuss current knowledge of these two groups of antibodies in terms of their discovery, how they arise, the interaction of both types of antibodies with their molecular targets, and the attempts that have been made to reproduce human neuronal injury in tissue culture models and experimental animals.
  • We then discuss the emerging area of autoimmune neuronal injury associated with immune checkpoint inhibitors and the implications of current research for the treatment of affected patients.

 

COVID-19 Antigen Rapid Test Pen (Saliva)

Panbio 2

The Rapid Response COVID-19 Antigen Rapid Test Pen (Saliva) is an in vitro immunoassay. The assay is for the direct and qualitative detection of SARS-CoV-2 viral nucleoprotein antigens from saliva samples through visual interpretation of colour development. This test is intended for professional use only.

Key Benefits:

• First and the only no-spit test dedicated to COVID-19 – Its sponge-like pen tip will collect a sufficient volume of specimen in 2 mins without the need to spit and avoiding uncomfortable nasal/throat swabbing.
• ALL IN ONE – No need to waste time setting up a workstation and handle numerous assay components. All you need is one pen that can be used comfortably in any location.

Test Principle 

Anti-SARS-CoV-2 antibodies are immobilized on the test region of the nitrocellulose membrane. Anti-SARS-CoV-2 antibodies conjugated to coloured particles are immobilized on the conjugated pad. A sample is added to the extraction buffer which is optimized to release the SARS-CoV-2 antigens from specimen. During testing, target antigens, if present in the saliva samples, will be released into the extraction buffer individually packed in the kit. Consequently, the extracted antigens will bind to anti-SARS-CoV-2 antibodies conjugated to coloured particles

As the specimen migrates along the strip by capillary action and interacts with reagents on the membrane, the complex will be captured by the anti-SARS-CoV-2 antibodies at the test region. Excess coloured particles are captured at the internal control zone. The presence of a coloured band in the test region indicates a positive result for the SARS-CoV-2 viral antigens, while its absence indicates a negative result. A coloured band at the control region serves as a procedural control, indicating that the proper volume of specimen has been added and membrane wicking is working.

 

ï¿­ INVBIO saliva alcohol screening test kit detects alcohol presence in saliva. Therefore, directly dipping the strip into alcohol alone will not provide you with an accurate reading.
ï¿­ It is very important that the test be read at exactly two minutes, The result you read 2 minutes after saturation with saliva is the accurate test result.
ï¿­Nothing should be placed into the mouth of the subject for at least 10 minutes prior to saliva collection. This includes food, drink, tobacco products or other materials.

SPECIMEN COLLECTION AND PREPARATION
ï¿­Nothing should be placed into the mouth of the subject for at least 10 minutes prior to saliva collection. This includes food, drink, tobacco products or other materials.
ï¿­ Saliva specimen can be collected in a sputum cup or a clean container, or directly applied to the reaction pad of the test strip.

PROCEDURE:
Open the foil package and remove the test strip.
Saturate the reactive pad by dipping the reaction pad into the saliva specimen collected in a cup, or saturate the reactive pad on the end of stick with saliva in mouth for 10 seconds, shake off the excess saliva.
Immediately start timer and at exactly 2 minutes, compare the reactive pad with the provided colored chart.
Results after more than 2 minutes may be not accurate.

INTERPRETATION OF RESULTS:
­ Negative: Almost no color change by comparing with the background. The negative result indicates that the BAC is less than 0.02%.
­ Positive: A distinct color developed all over the pad. The positive result indicates that the BAC is 0.02% or higher.
­ Invalid: The test should be considered invalid If only the edge of the reactive pad turned color that might be ascribed to insufficient sampling.

 

Luminex MAGPIX NATtrol

This examination was carried out to examine the results of indole-3-acetate sodium (IAA-Na) inclusion in diets on the egg manufacturing efficiency, egg high quality, intestinal tissue morphology, serum hormone ranges and biochemical parameters of Danzhou chickens to preliminarily discover the efficacy of IAA-Na as a feed additive. A complete of 192 Danzhou chickens (50 weeks previous) have been randomly assigned to 2 teams of 96. The diets for the therapy group consisted of basal diets, supplemented with IAA-Na (200 mg/kg).
The formal feeding trial lasted for 4 weeks. The outcomes confirmed that the feed supplemented with IAA-Na not solely elevated the laying charge (p < 0.05) and egg yolk ratio (0.05 < p < 0.1), but additionally considerably lowered the feed:egg ratio (p < 0.05). In addition, the dietary supplementation of IAA-Na considerably elevated the serum estradiol ranges (p < 0.05) and decreased serum alkaline phosphatase exercise (p < 0.05).
Compared with the management group, the addition of IAA-Na to the weight-reduction plan had no important impact on the intestinal tissue morphology or serum antioxidant capability of Danzhou chickens. This examination preliminarily gives proof that dietary IAA-Na can enhance laying efficiency, indicating that IAA-Na is a doubtlessly efficient feed additive for laying hens, however additional research are required earlier than arriving at particular conclusions.

Luminex MAGPIX NATtrol aimed zinc (Zn) supplementation and serum ranges of copeptin, high-sensitive C-reactive protein (hs-CRP), glycemic management, anthropometric parameters and renal operate in Zn -deficient diabetic hemodialysis patients (DHPs). This randomized, double-blind, placebo-controlled trial (RCT) was carried out on 46 DHPs with Zn-deficiency.

The Zn complement group (n = 21) acquired a 220-mg/day Zn sulfate capsule (containing 50 mg Zn), and the management group (n = 25) acquired a placebo capsule (220 mg corn starch), for eight weeks. Fasting, predialysis blood samples have been taken at baseline and after eight weeks to assess fasting blood glucose (FBG), serum insulin, copeptin, high-sensitive C-reactive protein (hs-CRP), blood urea nitrogen (BUN), creatinine (Cr) concentrations, and homoeostatic mannequin evaluation (HOMA-IR) and quantitative insulin-sensitivity verify index (QUICKI).
Compared to controls, serum copeptin (P < 0.001), hs-CRP (P < 0.001), BUN (P < 0.001), Cr (P < 0.001), Zn (P < 0.001), FBG (P < 0.001) ranges, BMI (P < 0.001), and physique weight (P < 0.001) have been considerably affected following ZnSO4 supplementation for eight weeks. In distinction, QUICKI (P = 0.57), HOMA-IR (P = 0.60), and serum insulin (P = 0.55) weren’t affected following Zn supplementation in comparability with patients receiving placebo. Zn sulfate supplementation seems to have favorable results on serum copeptin and hs-CRP, FBG, and renal operate in Zn-deficient DHPs. Iranian Registry of Clinical Trials Identifier: IRCT20190806044461N1.

Histopathological examination of newly-developed adhesive silicone denture relining material.

Histopathological examination of newly-developed adhesive silicone denture relining material.

We aimed to guage the subcutaneous tissue response to a newly developed adhesive silicone denture relining materials, SG, (Neo Dental Chemical Products Co., Ltd. Tokyo, Japan). We embedded the experimental materials SG and one other present management materials, Roeko Seal (RS), within the dorsal space of 22 male ddY mice.

One week and 12 weeks after the embedding, the tissues surrounding the embedded supplies had been eliminated and a histopathological examination was carried out. The outcomes reveal that the essential histopathological elements are the formation of granulation tissue and the change of the tissue to fibrous capsule over time.

The outcomes means that the newly-developed SG is secure as in contrast with the management RS, whose composition is comparable.

Histopathological examination of newly-developed adhesive silicone denture relining material.
Histopathological examination of newly-developed adhesive silicone denture relining materials.

Collaborative research on fifteen compounds within the rat-liver Comet assay built-in into 2- and 4-week repeat-dose research.

A collaborative trial was carried out to guage the likelihood of integrating the rat-liver Comet assay into repeat-dose toxicity research. Fourteen laboratories from Europe, Japan and the USA examined fifteen chemical compounds.

Two chemical compounds had been beforehand proven to induce micronuclei in an acute protocol, however had been discovered unfavorable in a 4-week Micronucleus (MN) Assay (benzo[a]pyrene and 1,2-dimethylhydrazine; Hamada et al., 2001); 4 genotoxic rat-liver carcinogens that had been unfavorable within the MN assay in bone marrow or blood (2,6-dinitrotoluene, dimethylnitrosamine, 1,2-dibromomethane, and 2-amino-3-methylimidazo[4,5-f]quinoline); three compounds used within the ongoing JaCVAM (Japanese Center for the Validation of Alternative Methods) validation research of the acute liver Comet assay (2,4-diaminotoluene, 2,6-diaminotoluene and acrylamide); three pharmaceutical-like compounds (chlordiazepoxide, pyrimethamine and gemifloxacin), and three non-genotoxic rodent liver carcinogens (methapyrilene, clofibrate and phenobarbital). Male rats obtained oral administrations of the take a look at compounds, each day for 2 or 4 weeks.

EDEM2 Antibody

1-CSB-PA030228
  • EUR 266.40
  • EUR 234.00
  • 100ug
  • 50ug
Description: A polyclonal antibody against EDEM2. Recognizes EDEM2 from Human. This antibody is Unconjugated. Tested in the following application: IHC, ELISA;IHC:1/100-1/300.ELISA:1/10000

EDEM2 Antibody

46557-100ul 100ul
EUR 302.4

EDEM2 Antibody

40055-100ul 100ul
EUR 468

EDEM2 Antibody

ABD9503 100 ug
EUR 525.6

EDEM2 siRNA

20-abx914951
  • EUR 661.20
  • EUR 878.40
  • 15 nmol
  • 30 nmol

pOTB7-EDEM2

PVT18710 2 ug
EUR 277.2

anti-EDEM2

YF-PA19809 50 ul
EUR 435.6
Description: Mouse polyclonal to EDEM2

anti-EDEM2

YF-PA19810 100 ug
EUR 483.6
Description: Rabbit polyclonal to EDEM2

EDEM2 Antibody

6633-100 each
EUR 418.8

EDEM2 Antibody

6633-30T each
EUR 175.2

EDEM2 Blocking Peptide

DF9503-BP 1mg
EUR 234

EDEM2 Conjugated Antibody

C46557 100ul
EUR 476.4

EDEM2 cloning plasmid

CSB-CL861146HU-10ug 10ug
EUR 451.2
Description: A cloning plasmid for the EDEM2 gene.

anti- EDEM2 antibody

FNab02632 100µg
EUR 606.3
Description: Antibody raised against EDEM2

EDEM2 Polyclonal Antibody

ES6755-100ul 100ul
EUR 334.8
Description: A Rabbit Polyclonal antibody against EDEM2 from Human. This antibody is tested and validated for IHC, WB, ELISA

EDEM2 Polyclonal Antibody

ES6755-50ul 50ul
EUR 248.4
Description: A Rabbit Polyclonal antibody against EDEM2 from Human. This antibody is tested and validated for IHC, WB, ELISA

EDEM2 Polyclonal Antibody

ABP55756-003ml 0.03ml
EUR 189.6
Description: A polyclonal antibody for detection of EDEM2 from Human. This EDEM2 antibody is for IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human EDEM2

EDEM2 Polyclonal Antibody

ABP55756-01ml 0.1ml
EUR 346.8
Description: A polyclonal antibody for detection of EDEM2 from Human. This EDEM2 antibody is for IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human EDEM2

EDEM2 Polyclonal Antibody

ABP55756-02ml 0.2ml
EUR 496.8
Description: A polyclonal antibody for detection of EDEM2 from Human. This EDEM2 antibody is for IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human EDEM2

Polyclonal EDEM2 Antibody

AMM07003G 0.1mg
EUR 580.8
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human EDEM2 . This antibody is tested and proven to work in the following applications:

Anti-EDEM2 antibody

PAab02632 100 ug
EUR 426

Anti-EDEM2 antibody

STJ92823 200 µl
EUR 236.4
Description: Rabbit polyclonal to EDEM2.

Anti-EDEM2 (2E4)

YF-MA11569 100 ug
EUR 435.6
Description: Mouse monoclonal to EDEM2

EDEM2 Polyclonal Antibody

A58890-020 20 ul
EUR 117.7

EDEM2 Polyclonal Antibody

A58890-050 50 ul
EUR 302.5

EDEM2 Polyclonal Antibody

A58890-100 100 ul
EUR 423.5

EDEM2 Polyclonal Antibody

A58890
  • EUR 684.66
  • EUR 117.70
  • EUR 302.50
  • EUR 423.50
  • 100 µg
  • 20 ul
  • 50 ul
  • 100 ul

EDEM2 Blocking Peptide

6633BP-50 each
EUR 183.6

Human EDEM2 shRNA Plasmid

20-abx960878
  • EUR 961.20
  • EUR 1345.20
  • 150 µg
  • 300 µg

EDEM2 Antibody, HRP conjugated

1-CSB-PA861146LB01HU
  • EUR 380.40
  • EUR 402.00
  • 100ug
  • 50ug
Description: A polyclonal antibody against EDEM2. Recognizes EDEM2 from Human. This antibody is HRP conjugated. Tested in the following application: ELISA

EDEM2 Antibody, FITC conjugated

1-CSB-PA861146LC01HU
  • EUR 380.40
  • EUR 402.00
  • 100ug
  • 50ug
Description: A polyclonal antibody against EDEM2. Recognizes EDEM2 from Human. This antibody is FITC conjugated. Tested in the following application: ELISA

EDEM2 Antibody, Biotin conjugated

1-CSB-PA861146LD01HU
  • EUR 380.40
  • EUR 402.00
  • 100ug
  • 50ug
Description: A polyclonal antibody against EDEM2. Recognizes EDEM2 from Human. This antibody is Biotin conjugated. Tested in the following application: ELISA

Human EDEM2 ELISA KIT

ELI-32317h 96 Tests
EUR 988.8

EDEM2 ELISA KIT|Human

EF009290 96 Tests
EUR 826.8

EDEM2 Recombinant Protein (Mouse)

RP130856 100 ug Ask for price

EDEM2 Recombinant Protein (Rat)

RP199049 100 ug Ask for price

EDEM2 Recombinant Protein (Human)

RP010159 100 ug Ask for price

Edem2 ORF Vector (Rat) (pORF)

ORF066351 1.0 ug DNA
EUR 607.2

EDEM2 ORF Vector (Human) (pORF)

ORF003387 1.0 ug DNA
EUR 114

Edem2 ORF Vector (Mouse) (pORF)

ORF043620 1.0 ug DNA
EUR 607.2

EDEM2 Polyclonal Antibody, Biotin Conjugated

A58891-050 50 ul
EUR 302.5

EDEM2 Polyclonal Antibody, Biotin Conjugated

A58891-100 100 ul
EUR 423.5

EDEM2 Polyclonal Antibody, FITC Conjugated

A58892-050 50 ul
EUR 302.5

EDEM2 Polyclonal Antibody, FITC Conjugated

A58892-100 100 ul
EUR 423.5

EDEM2 Polyclonal Antibody, HRP Conjugated

A58893-050 50 ul
EUR 302.5

EDEM2 Polyclonal Antibody, HRP Conjugated

A58893-100 100 ul
EUR 423.5

EDEM2 Polyclonal Antibody, Biotin Conjugated

A58891
  • EUR 684.66
  • EUR 302.50
  • EUR 423.50
  • 100 µg
  • 50 ul
  • 100 ul

EDEM2 Polyclonal Antibody, FITC Conjugated

A58892
  • EUR 684.66
  • EUR 302.50
  • EUR 423.50
  • 100 µg
  • 50 ul
  • 100 ul

EDEM2 Polyclonal Antibody, HRP Conjugated

A58893
  • EUR 684.66
  • EUR 302.50
  • EUR 423.50
  • 100 µg
  • 50 ul
  • 100 ul

EDEM2 sgRNA CRISPR Lentivector set (Human)

K0653501 3 x 1.0 ug
EUR 406.8

Edem2 sgRNA CRISPR Lentivector set (Mouse)

K3235601 3 x 1.0 ug
EUR 406.8

Edem2 sgRNA CRISPR Lentivector set (Rat)

K7428201 3 x 1.0 ug
EUR 406.8

Monoclonal EDEM2 Antibody (clone 2E4), Clone: 2E4

AMM07004G 0.05mg
EUR 633.6
Description: A Monoclonal antibody against Human EDEM2 (clone 2E4). The antibodies are raised in Mouse and are from clone 2E4. This antibody is applicable in WB and IHC-P, E

EDEM2 sgRNA CRISPR Lentivector (Human) (Target 1)

K0653502 1.0 ug DNA
EUR 184.8

EDEM2 sgRNA CRISPR Lentivector (Human) (Target 2)

K0653503 1.0 ug DNA
EUR 184.8

EDEM2 sgRNA CRISPR Lentivector (Human) (Target 3)

K0653504 1.0 ug DNA
EUR 184.8

Edem2 sgRNA CRISPR Lentivector (Mouse) (Target 1)

K3235602 1.0 ug DNA
EUR 184.8

Edem2 sgRNA CRISPR Lentivector (Mouse) (Target 2)

K3235603 1.0 ug DNA
EUR 184.8

Edem2 sgRNA CRISPR Lentivector (Mouse) (Target 3)

K3235604 1.0 ug DNA
EUR 184.8

Edem2 sgRNA CRISPR Lentivector (Rat) (Target 1)

K7428202 1.0 ug DNA
EUR 184.8

Edem2 sgRNA CRISPR Lentivector (Rat) (Target 2)

K7428203 1.0 ug DNA
EUR 184.8

Edem2 sgRNA CRISPR Lentivector (Rat) (Target 3)

K7428204 1.0 ug DNA
EUR 184.8

EDEM2 Protein Vector (Human) (pPB-C-His)

PV013545 500 ng
EUR 394.8

EDEM2 Protein Vector (Human) (pPB-N-His)

PV013546 500 ng
EUR 394.8

EDEM2 Protein Vector (Human) (pPM-C-HA)

PV013547 500 ng
EUR 394.8

EDEM2 Protein Vector (Human) (pPM-C-His)

PV013548 500 ng
EUR 394.8

EDEM2 Protein Vector (Mouse) (pPB-C-His)

PV174478 500 ng
EUR 723.6

EDEM2 Protein Vector (Mouse) (pPB-N-His)

PV174479 500 ng
EUR 723.6

EDEM2 Protein Vector (Mouse) (pPM-C-HA)

PV174480 500 ng
EUR 723.6

EDEM2 Protein Vector (Mouse) (pPM-C-His)

PV174481 500 ng
EUR 723.6

EDEM2 Protein Vector (Rat) (pPB-C-His)

PV265402 500 ng
EUR 723.6

EDEM2 Protein Vector (Rat) (pPB-N-His)

PV265403 500 ng
EUR 723.6

EDEM2 Protein Vector (Rat) (pPM-C-HA)

PV265404 500 ng
EUR 723.6

EDEM2 Protein Vector (Rat) (pPM-C-His)

PV265405 500 ng
EUR 723.6

EDEM2 3'UTR Luciferase Stable Cell Line

TU006560 1.0 ml
EUR 1672.8

Edem2 3'UTR Luciferase Stable Cell Line

TU203777 1.0 ml Ask for price

Edem2 3'UTR GFP Stable Cell Line

TU253777 1.0 ml Ask for price

Edem2 3'UTR GFP Stable Cell Line

TU155598 1.0 ml Ask for price

Edem2 3'UTR Luciferase Stable Cell Line

TU105598 1.0 ml Ask for price

EDEM2 3'UTR GFP Stable Cell Line

TU056560 1.0 ml
EUR 1672.8

EDEM2 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC)

LV791509 1.0 ug DNA
EUR 379.2

EDEM2 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a)

LV791510 1.0 ug DNA
EUR 379.2

EDEM2 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV)

LV650983 1.0 ug DNA
EUR 818.4

EDEM2 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC)

LV650987 1.0 ug DNA
EUR 818.4

EDEM2 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a)

LV650988 1.0 ug DNA
EUR 818.4

ER Degradation Enhancer, Mannosidase Alpha-Like 2 (EDEM2) Antibody

abx036086-100ug 100 ug
EUR 469.2

ER Degradation Enhancer, Mannosidase Alpha-Like 2 (EDEM2) Antibody

abx232632-100ug 100 ug
EUR 577.2

ER Degradation Enhancer, Mannosidase alpha-Like 2 (EDEM2) Antibody

20-abx322885
  • EUR 376.80
  • EUR 292.80
  • 100 ug
  • 50 ug

ER Degradation Enhancer, Mannosidase Alpha-Like 2 (EDEM2) Antibody

20-abx310614
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

ER Degradation Enhancer, Mannosidase Alpha-Like 2 (EDEM2) Antibody (HRP)

20-abx310615
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

ER Degradation Enhancer, Mannosidase Alpha-Like 2 (EDEM2) Antibody (FITC)

20-abx310616
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

ER Degradation Enhancer, Mannosidase Alpha-Like 2 (EDEM2) Antibody (Biotin)

20-abx310617
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

EDEM2 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human)

K0653505 3 x 1.0 ug
EUR 451.2

Edem2 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Mouse)

K3235605 3 x 1.0 ug
EUR 451.2

Edem2 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Rat)

K7428205 3 x 1.0 ug
EUR 451.2

Human ER Degradation Enhancer, Mannosidase alpha-Like 2 (EDEM2) ELISA Kit

abx387046-96tests 96 tests
EUR 1093.2

EDEM2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1)

K0653506 1.0 ug DNA
EUR 200.4

EDEM2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 2)

K0653507 1.0 ug DNA
EUR 200.4

EDEM2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 3)

K0653508 1.0 ug DNA
EUR 200.4

EDEM2 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro)

LV791507 1.0 ug DNA
EUR 448.8

EDEM2 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro)

LV791508 1.0 ug DNA
EUR 448.8

EDEM2 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA)

LV650984 1.0 ug DNA
EUR 818.4

EDEM2 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro)

LV650985 1.0 ug DNA
EUR 888

EDEM2 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro)

LV650986 1.0 ug DNA
EUR 888

Edem2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 1)

K3235606 1.0 ug DNA
EUR 200.4

Edem2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 2)

K3235607 1.0 ug DNA
EUR 200.4

Edem2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 3)

K3235608 1.0 ug DNA
EUR 200.4

Edem2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 1)

K7428206 1.0 ug DNA
EUR 200.4

Edem2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 2)

K7428207 1.0 ug DNA
EUR 200.4

Edem2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 3)

K7428208 1.0 ug DNA
EUR 200.4

The prime dose was meant to be the very best dose producing scientific indicators or histopathological results with out inflicting mortality, i.e. the 28-day most tolerated dose. The liver Comet assay was carried out in accordance with revealed suggestions and following the protocol for the continuing JaCVAM validation trial. Laboratories supplied liver Comet assay knowledge obtained on the finish of the long-term (2- or 4-week) research along with an analysis of liver histology.

Most of the take a look at compounds had been additionally investigated within the liver Comet assay after short-term (1-Three each day) administration to match the sensitivity of the 2 research designs. MN analyses had been carried out in bone marrow or peripheral blood for many of the compounds to find out whether or not the liver Comet assay might complement the MN assay for the detection of genotoxins after long-term therapy.

Most of the liver genotoxins had been optimistic and the three non-genotoxic carcinogens gave unfavorable end result within the liver Comet assay after long-term administration. There was a excessive concordance between short- and long-term Comet assay outcomes. Most compounds when examined as much as the utmost tolerated dose had been accurately detected in each short- and long-term research.

Discrepant outcomes had been obtained with 2,6 diaminotoluene (unfavorable within the short-term, however optimistic within the long-term research), phenobarbital (optimistic within the short-term, however unfavorable within the long-term research) and gemifloxacin (optimistic within the short-term, however unfavorable within the long-term research).

The total outcomes point out that the liver Comet assay will be built-in inside repeat-dose toxicity research and effectively enhances the MN assay in detecting genotoxins. Practical elements of integrating genotoxicity endpoints into repeat-dose research had been evaluated, e.g. by investigating the impact of blood sampling, as usually carried out throughout toxicity research, on the Comet and MN assays.

The bleeding protocols used right here didn’t have an effect on the conclusions of the Comet assay or of the MN assays in blood and bone marrow. Although bleeding typically elevated reticulocyte frequencies, the sensitivity of the response within the MN assay was not altered. 

FLX pyrosequencing analysis of the effects of the brown-algal fermentable polysaccharides alginate and laminaran on rat cecal microbiotas.

FLX pyrosequencing analysis of the effects of the brown-algal fermentable polysaccharides alginate and laminaran on rat cecal microbiotas.

Edible brown algae are used as main meals materials in Far East Asian international locations, significantly in South Korea and Japan. They comprise fermentable dietary fibers, alginic acid (uronic acid polymer) and laminaran (β-1,3-glucan), which can be fermented into natural acids by intestinal micro organism.

To make clear the impact of edible algae on the intestinal setting, the cecal microbiotas of rats fed diets containing no dietary fiber (management) or 2% (wt/wt) sodium alginate or laminaran for two weeks have been analyzed utilizing FLX amplicon pyrosequencing with bar-coded primers focusing on the bacterial 16S rRNA gene. The most considerable phylum in all teams was Firmicutes.

Specifically, Allobaculum was dominant in all food regimen teams. In addition, Bacteroides capillosus (37.1%) was considerable in the alginate group, whereas Clostridium ramosum (3.14%) and Parabacteroides distasonis (1.36%) have been solely detected in the laminaran group. Furthermore, rats fed alginate confirmed simplified microbiota phylotypes in contrast with others. With respect to cecal chemical compounds, laminaran increased cecal natural acid ranges, significantly propionic acid. Alginate elevated complete cecal natural acids.

Cecal putrefactive compounds, comparable to indole, H(2)S, and phenol, have been decreased by each alginate and laminaran. These outcomes point out that edible brown algae can alter the intestinal setting, with fermentation by intestinal microbiota.

FLX pyrosequencing analysis of the effects of the brown-algal fermentable polysaccharides alginate and laminaran on rat cecal microbiotas.
FLX pyrosequencing analysis of the effects of the brown-algal fermentable polysaccharides alginate and laminaran on rat cecal microbiotas.

Tsunami lung.

We encountered three instances of lung issues attributable to drowning in the current massive tsunami that struck following the Great East Japan Earthquake. All three have been females, and two of them have been outdated aged. All segments of each lungs have been concerned in all the three sufferers, necessitating ICU admission and endotracheal intubation and mechanical air flow. All three died inside 3 weeks.

EDEM3 Antibody

ABD9504 100 ug
EUR 525.6

EDEM3 siRNA

20-abx914952
  • EUR 661.20
  • EUR 878.40
  • 15 nmol
  • 30 nmol

EDEM3 siRNA

20-abx914953
  • EUR 661.20
  • EUR 878.40
  • 15 nmol
  • 30 nmol

EDEM3 Antibody

DF9504 200ul
EUR 420

EDEM3 Antibody

RQ6618 100ug
EUR 419
Description: ER degradation-enhancing alpha-mannosidase-like 3 is an enzyme that in humans is encoded by the EDEM3 gene. Quality control in the endoplasmic reticulum (ER) ensures that only properly folded proteins are retained in the cell through recognition and degradation of misfolded or unassembled proteins. EDEM3 belongs to a group of proteins that accelerate degradation of misfolded glycoproteins in the ER.

EDEM3 Polyclonal Antibody

ABP58454-003ml 0.03ml
EUR 189.6
Description: A polyclonal antibody for detection of EDEM3 from Human, Mouse. This EDEM3 antibody is for WB, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human EDEM3 protein

EDEM3 Polyclonal Antibody

ABP58454-01ml 0.1ml
EUR 346.8
Description: A polyclonal antibody for detection of EDEM3 from Human, Mouse. This EDEM3 antibody is for WB, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human EDEM3 protein

EDEM3 Polyclonal Antibody

ABP58454-02ml 0.2ml
EUR 496.8
Description: A polyclonal antibody for detection of EDEM3 from Human, Mouse. This EDEM3 antibody is for WB, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human EDEM3 protein

Polyclonal EDEM3 Antibody

AMM07005G 0.1mg
EUR 633.6
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human EDEM3 . This antibody is tested and proven to work in the following applications:

EDEM3 cloning plasmid

CSB-CL863170HU-10ug 10ug
EUR 279.6
Description: A cloning plasmid for the EDEM3 gene.

EDEM3 Conjugated Antibody

C45972 100ul
EUR 476.4

EDEM3 Blocking Peptide

DF9504-BP 1mg
EUR 234

EDEM3 Polyclonal Antibody

ES9649-100ul 100ul
EUR 334.8
Description: A Rabbit Polyclonal antibody against EDEM3 from Human/Mouse. This antibody is tested and validated for WB, ELISA, WB, ELISA

EDEM3 Polyclonal Antibody

ES9649-50ul 50ul
EUR 248.4
Description: A Rabbit Polyclonal antibody against EDEM3 from Human/Mouse. This antibody is tested and validated for WB, ELISA, WB, ELISA

Anti-EDEM3 antibody

STJ190807 200 µl
EUR 236.4
Description: Unconjugated Rabbit polyclonal to EDEM3

EDEM3 Blocking Peptide

3614BP-50 each
EUR 183.6

Human EDEM3 shRNA Plasmid

20-abx962830
  • EUR 961.20
  • EUR 1345.20
  • 150 µg
  • 300 µg

Mouse EDEM3 shRNA Plasmid

20-abx975889
  • EUR 961.20
  • EUR 1345.20
  • 150 µg
  • 300 µg

Mouse Edem3 ELISA KIT

ELI-26645m 96 Tests
EUR 1038

Human EDEM3 ELISA KIT

ELI-47172h 96 Tests
EUR 988.8

Edem3 ORF Vector (Rat) (pORF)

ORF066352 1.0 ug DNA
EUR 607.2

EDEM3 ORF Vector (Human) (pORF)

ORF003388 1.0 ug DNA
EUR 114

Edem3 ORF Vector (Mouse) (pORF)

ORF043621 1.0 ug DNA
EUR 607.2

EDEM3 sgRNA CRISPR Lentivector set (Human)

K0653601 3 x 1.0 ug
EUR 406.8

Edem3 sgRNA CRISPR Lentivector set (Rat)

K6190401 3 x 1.0 ug
EUR 406.8

Edem3 sgRNA CRISPR Lentivector set (Mouse)

K3468201 3 x 1.0 ug
EUR 406.8

EDEM3 sgRNA CRISPR Lentivector (Human) (Target 1)

K0653602 1.0 ug DNA
EUR 184.8

EDEM3 sgRNA CRISPR Lentivector (Human) (Target 2)

K0653603 1.0 ug DNA
EUR 184.8

EDEM3 sgRNA CRISPR Lentivector (Human) (Target 3)

K0653604 1.0 ug DNA
EUR 184.8

Edem3 sgRNA CRISPR Lentivector (Rat) (Target 1)

K6190402 1.0 ug DNA
EUR 184.8

Edem3 sgRNA CRISPR Lentivector (Rat) (Target 2)

K6190403 1.0 ug DNA
EUR 184.8

Edem3 sgRNA CRISPR Lentivector (Rat) (Target 3)

K6190404 1.0 ug DNA
EUR 184.8

Edem3 sgRNA CRISPR Lentivector (Mouse) (Target 1)

K3468202 1.0 ug DNA
EUR 184.8

Edem3 sgRNA CRISPR Lentivector (Mouse) (Target 2)

K3468203 1.0 ug DNA
EUR 184.8

Edem3 sgRNA CRISPR Lentivector (Mouse) (Target 3)

K3468204 1.0 ug DNA
EUR 184.8

EDEM3 Protein Vector (Human) (pPB-C-His)

PV013549 500 ng
EUR 394.8

EDEM3 Protein Vector (Human) (pPB-N-His)

PV013550 500 ng
EUR 394.8

EDEM3 Protein Vector (Human) (pPM-C-HA)

PV013551 500 ng
EUR 394.8

EDEM3 Protein Vector (Human) (pPM-C-His)

PV013552 500 ng
EUR 394.8

EDEM3 Protein Vector (Mouse) (pPB-C-His)

PV174482 500 ng
EUR 1278

EDEM3 Protein Vector (Mouse) (pPB-N-His)

PV174483 500 ng
EUR 1278

EDEM3 Protein Vector (Mouse) (pPM-C-HA)

PV174484 500 ng
EUR 1278

EDEM3 Protein Vector (Mouse) (pPM-C-His)

PV174485 500 ng
EUR 1278

EDEM3 3'UTR Luciferase Stable Cell Line

TU006561 1.0 ml
EUR 2799.6

Edem3 3'UTR GFP Stable Cell Line

TU253778 1.0 ml Ask for price

Edem3 3'UTR Luciferase Stable Cell Line

TU105599 1.0 ml Ask for price

EDEM3 3'UTR GFP Stable Cell Line

TU056561 1.0 ml
EUR 2799.6

Edem3 3'UTR Luciferase Stable Cell Line

TU203778 1.0 ml Ask for price

Edem3 3'UTR GFP Stable Cell Line

TU155599 1.0 ml Ask for price

EDEM3 Protein Vector (Rat) (pPB-C-His)

PV265406 500 ng
EUR 1399.2

EDEM3 Protein Vector (Rat) (pPB-N-His)

PV265407 500 ng
EUR 1399.2

EDEM3 Protein Vector (Rat) (pPM-C-HA)

PV265408 500 ng
EUR 1399.2

EDEM3 Protein Vector (Rat) (pPM-C-His)

PV265409 500 ng
EUR 1399.2

ER Degradation-Enhancing Alpha-Mannosidase-Like Protein 3 (EDEM3) Antibody

abx028901-400ul 400 ul
EUR 627.6

ER Degradation-Enhancing Alpha-Mannosidase-Like Protein 3 (EDEM3) Antibody

abx028901-80l 80 µl
EUR 343.2

ER Degradation-Enhancing Alpha-Mannosidase-Like Protein 3 (EDEM3) Antibody

20-abx215068
  • EUR 510.00
  • EUR 410.40
  • 100 ug
  • 50 ug

EDEM3 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human)

K0653605 3 x 1.0 ug
EUR 451.2

Edem3 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Rat)

K6190405 3 x 1.0 ug
EUR 451.2

Edem3 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Mouse)

K3468205 3 x 1.0 ug
EUR 451.2

EDEM3 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1)

K0653606 1.0 ug DNA
EUR 200.4

EDEM3 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 2)

K0653607 1.0 ug DNA
EUR 200.4

EDEM3 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 3)

K0653608 1.0 ug DNA
EUR 200.4

Edem3 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 1)

K6190406 1.0 ug DNA
EUR 200.4

Edem3 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 2)

K6190407 1.0 ug DNA
EUR 200.4

Edem3 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 3)

K6190408 1.0 ug DNA
EUR 200.4

Edem3 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 1)

K3468206 1.0 ug DNA
EUR 200.4

Edem3 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 2)

K3468207 1.0 ug DNA
EUR 200.4

Edem3 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 3)

K3468208 1.0 ug DNA
EUR 200.4

In no less than two instances, misswallowing of oil was suspected from the options famous at the time of the detection. Sputum tradition for micro organism yielded isolation of Stenotrophomonas maltophilia, Legionella pneumophila, Burkholderia cepacia, and Pseudomonas aeruginosa. The trigger of tsunami lung could also be a mix of chemical induced pneumonia and bacterial pneumonia.

Cultivated oral mucosal epithelial transplantation for persistent epithelial defect in severe ocular surface diseases with acute inflammatory activity.

OBJECTIVE
To assess the medical efficacy of cultivated oral mucosal epithelial transplantation (COMET) for the remedy of persistent epithelial defect (PED).
METHODS
We handled 10 eyes of 9 sufferers with PED (Stevens-Johnson syndrome: three eyes; thermal/chemical harm: 5 eyes; ocular cicatricial pemphigoid: two eyes) with COMET at Kyoto Prefectural University of Medicine, Kyoto, Japan from 2002 to 2008.
RESULTS
Preoperatively, PED existed on over greater than 50% of the corneal surface in seven eyes. Severe ocular surface irritation with fibrovascular tissue surrounded the PED in all 10 eyes. At 24-weeks postoperative, PED had improved in all instances besides 1 in which the affected person was unable to return to the hospital (95% CI, 55.5-99.7; Wilcoxon signed-rank check, p = 0.0078).
The preoperative median of logarithmic minimal angle of decision was 1.85 (vary 0.15-2.70), and 1.85, 1.85, and 1.52 on the 4th, 12th, and 24th postoperative week, respectively.
The imply whole preoperative ocular surface grading rating was 7.0 (vary 4-17). At Four and 12 weeks postoperative, the whole ocular surface grading rating had improved considerably (p = 0.0020, p = 0.0078), and at 24 weeks postoperative, it was 3.0 (vary 2-12, p = 0.0234). During the follow-up interval (median 23.Three months, vary 5.6-39.7 months), no recurrence of PED was noticed in any eye, and long-term ocular surface stability was obtained.
CONCLUSIONS
COMET enabled full epithelialization of PED and stabilization of the ocular surface in sufferers with severe ocular surface illness, thus stopping end-stage cicatrization and imaginative and prescient loss at a later stage.
 Cultivated oral mucosal epithelial transplantation for persistent epithelial defect in severe ocular surface diseases with acute inflammatory activity.
Cultivated oral mucosal epithelial transplantation for persistent epithelial defect in severe ocular surface diseases with acute inflammatory exercise.

Antianxiety-like results of Chimpi (dried citrus peels) in the elevated open-platform check.

Dried citrus peels (Chimpi) is likely one of the most typical pure medicines with qi (power circulate) rectifying and shi (dampness) drying actions, which originates from Citrus unshiu, and/or C. reticulata in response to the definition of the pharmacopoeiae of Japan and China. In this examine, the pharmacological results of their extracts and main chemical constituents hesperidin and its aglycone hesperetin on nervousness had been examined with an nervousness mannequin of elevated open-platform check utilizing ICR male mice (6-week-old) and whole period of freezing was decreased in fluoxetine-treated mice, which is a straightforward and extremely delicate to the consequences of serotonergic anxiolytics.

EDTA, Disodium Salt, Dihydrate

CH034 2.5 kg
EUR 400.8

EDTA, disodium salt, dihydrate

EB0185 500g
EUR 84.01

EDTA disodium salt dihydrate

GE3023-100G 100 g
EUR 48

EDTA disodium salt dihydrate

GE3023-1KG 1 kg
EUR 84

EDTA disodium salt dihydrate

GE3023-250G 250 g
EUR 55.2

EDTA disodium salt dihydrate

GE3023-500G 500 g
EUR 64.8

EDTA disodium salt dihydrate

GE3023-5KG 5 kg
EUR 180

EDTA disodium and monocalcium salt

EK014P2 500g
EUR 115.33

EDTA copper(II) disodium salt

EB0434 250g
EUR 100.72

EDTA disodium and monomagnesium salt

EB0435 500g
EUR 133.08

EDTA zinc (II), disodium salt

EB6666 100g
EUR 77.75

EDTA magnesium disodium salt hydrate

GE3956-100G 100 g
EUR 79.2

EDTA magnesium disodium salt hydrate

GE3956-1KG 1 kg
EUR 294

EDTA magnesium disodium salt hydrate

GE3956-250G 250 g
EUR 122.4

EDTA magnesium disodium salt hydrate

GE3956-25G 25 g
EUR 54

EDTA magnesium disodium salt hydrate

GE3956-500G 500 g
EUR 184.8

EDTA disodium zinc salt hydrate

GX3802-100G 100 g
EUR 64.8

EDTA disodium zinc salt hydrate

GX3802-250G 250 g
EUR 90

EDTA disodium zinc salt hydrate

GX3802-25G 25 g
EUR 51.6

EDTA disodium zinc salt hydrate

GX3802-500G 500 g
EUR 132

EDTA manganese disodium salt hydrate

GX6009-100G 100 g
EUR 122.4

EDTA manganese disodium salt hydrate

GX6009-250G 250 g
EUR 208.8

EDTA manganese disodium salt hydrate

GX6009-25G 25 g
EUR 69.6

EDTA manganese disodium salt hydrate

GX6009-500G 500 g
EUR 322.8

EDTA Disodium Salt 0.02m (0.04n)

ED20021 1L
EUR 127.68

Volumetric Sol EDTA (DiSodium Salt) 0.002M (0.004N)

ED200021 1L
EUR 43.32

Volumetric Sol EDTA (DiSodium Salt) 0.002M (0.004N)

ED200025 5L
EUR 120.84

Volumetric Sol EDTA (DiSodium Salt) 0.01M (0.02N)

ED20011 1L
EUR 21.66

Volumetric Sol EDTA (DiSodium Salt) 0.01M (0.02N)

ED20015 5L
EUR 58.14

Volumetric Sol EDTA (DiSodium Salt) 0.025M (0.05N)

ED200251 1L
EUR 247.38

Volumetric Sol EDTA (DiSodium Salt) 0.01785M (0.0357N)

ED2003571 1L
EUR 90.06

Volumetric Sol EDTA (DiSodium Salt) 0.05M (0.10N)

ED20051 1L
EUR 49.02

Volumetric Sol EDTA (DiSodium Salt) 0.1M (0.2N)

ED2011 1L
EUR 29.64

Volumetric Sol EDTA (DiSodium Salt) 0.1M (0.2N)

ED2015 5L
EUR 92.34

Volumetric Sol EDTA (DiSodium Salt) 0.01M (0.02N)

EDB200110 10L
EUR 116.28

Volumetric Sol EDTA (DiSodium Salt) 0.027M (0.054N)

EDB200271 1L
EUR 28.5

Volumetric Sol EDTA (DiSodium Salt) 0.1M (0.2N)

EDB20110 10L
EUR 169.86

EDTA, Disodium Dihydrate Salt Ultra Pure Grade

20-147 500g/Unit
EUR 366

0.5M EDTA

EDTA-150 150 µL
EUR 15
Description: 0.5M EDTA used for preparation of urine samples for use with the Oxalate Quick Test Strips. Quantity: 150 µL 0.5M EDTA.

Volumetric Sol EDTA (DiSodium Salt) 0.027M (Bag In Box)

EDB20027 10L
EUR 214.32

Volumetric Sol EDTA (DiSodium Salt) 0.1M (Bag In Box)

EDB20105 5L
EUR 141.36

Carbenicillin, Disodium Salt

A2511-5.1 10 mM (in 1mL DMSO)
EUR 129.6
Description: Carbenicillin inhibits the cell-wall synthesis (peptidoglycan cross-linking) by inactivating transpeptidase on the inner surface of the bacterial cell membrane.Carbenicillin is a white to slightly yellow, hygroscopic powder soluble in water and in alcohol.

Carbenicillin, Disodium Salt

A2511-50 50 mg
EUR 157.2
Description: Carbenicillin inhibits the cell-wall synthesis (peptidoglycan cross-linking) by inactivating transpeptidase on the inner surface of the bacterial cell membrane.Carbenicillin is a white to slightly yellow, hygroscopic powder soluble in water and in alcohol.

DNQX disodium salt

B5288-100 100 mg
EUR 334.8

DNQX disodium salt

B5288-25 25 mg
EUR 153.6

DNQX disodium salt

B5288-50 50 mg
EUR 223.2

NBQX disodium salt

B6566-10 10 mg
EUR 266.4

NBQX disodium salt

B6566-25 25 mg
EUR 466.8

NBQX disodium salt

B6566-5 5 mg
EUR 166.8

NBQX disodium salt

B6566-50 50 mg
EUR 819.6

CNQX disodium salt

B6567-1 1 mg
EUR 160.8

CNQX disodium salt

B6567-10 10 mg
EUR 258

CNQX disodium salt

B6567-50 50 mg
EUR 895.2

UDP disodium salt

B7278-5.1 10 mM (in 1mL DMSO)
EUR 129.6

UDP disodium salt

B7278-50 50 mg
EUR 150

Phosphocreatine disodium salt

B7648-25 25 mg
EUR 235.2

BCIP disodium salt

BB1171 500mg
EUR 279.24

ATP disodium salt

B3304-5.1 10 mM (in 1mL H2O)
EUR 129.6
Description: ATP Disodium salt is a P2 purinoceptor agonist.

ATP disodium salt

B3304-50 50 mg
EUR 153.6
Description: ATP Disodium salt is a P2 purinoceptor agonist.

ATP disodium salt

B3304-S Evaluation Sample
EUR 97.2
Description: ATP Disodium salt is a P2 purinoceptor agonist.

Phosphoramidon Disodium Salt

B4790-25 25 mg
EUR 588
Description: Phosphoramidon Disodium Salt is a potent inhibitor of metalloproteinase [1]. Metalloproteinase is an enzyme whose catalytic mechanism involves a metal. Most metalloproteases require zinc and some require cobalt.

Phosphoramidon Disodium Salt

B4790-5 5 mg
EUR 226.8
Description: Phosphoramidon Disodium Salt is a potent inhibitor of metalloproteinase [1]. Metalloproteinase is an enzyme whose catalytic mechanism involves a metal. Most metalloproteases require zinc and some require cobalt.

Dimethylglyoxime disodium salt

DD1221 100g
EUR 76.7

cGAMP disodium salt

GL2101-100UG 100 ug
EUR 192

cGAMP disodium salt

GL2101-500UG 500 ug
EUR 398.4

Etidronate disodium salt

GP3560-1G 1 g
EUR 208.8

Lobenzarit disodium salt

GP3753-100MG 100 mg
EUR 274.8

ATP (disodium salt)

HY-B0345A 10mM/1mL
EUR 135.6

Methoxatin (disodium salt)

HY-100196A 10mM/1mL
EUR 223.2

Carbenicillin disodium salt

GA1299-10G 10 g
EUR 274.8

Carbenicillin disodium salt

GA1299-1G 1 g
EUR 103.2

Carbenicillin disodium salt

GA1299-250MG 250 mg
EUR 70.8

Carbenicillin disodium salt

GA1299-25G 25 g
EUR 409.2

Carbenicillin disodium salt

GA1299-5G 5 g
EUR 189.6

Ticarcillin disodium salt

GA1874-100MG 100 mg
EUR 60

Ticarcillin disodium salt

GA1874-1G 1 g
EUR 132

Ticarcillin disodium salt

GA1874-500MG 500 mg
EUR 93.6

Cefotetan disodium salt

GA5476-100MG 100 mg
EUR 103.2

Cefotetan disodium salt

GA5476-1G 1 g
EUR 217.2

Phosphomycin disodium salt

GA7173-1G 1 g
EUR 84

Phosphomycin disodium salt

GA7173-25G 25 g
EUR 346.8

Phosphomycin disodium salt

GA7173-5G 5 g
EUR 160.8

ADA disodium salt

GB0256-100G 100 g
EUR 132

ADA disodium salt

GB0256-500G 500 g
EUR 409.2

PIPES disodium salt

GB1799-100G 100 g
EUR 132

PIPES disodium salt

GB1799-250G 250 g
EUR 217.2

PIPES disodium salt

GB1799-25G 25 g
EUR 84

PIPES disodium salt

GB1799-500G 500 g
EUR 370.8

POPSO disodium salt

GB6170-100G 100 g
EUR 322.8

POPSO disodium salt

GB6170-25G 25 g
EUR 151.2

NADH (disodium salt)

HY-F0001 10mM/1mL
EUR 135.6

NADP (disodium salt)

HY-F0002A 500mg
EUR 325.2

Fluorescein, disodium salt

FB0203 100g
EUR 76.7

Balsalazide disodium salt

GP7647-1G 1 g
EUR 132

POPSO, disodium salt

PB4959 25g
EUR 92.36

Hypoxanthine Disodium Salt

B1185-1G each
EUR 130.8

Hypoxanthine Disodium Salt

B1185-5G each
EUR 288

cGAMP disodium salt

2435-100 each
EUR 235.2

NADH, disodium salt

2735-1000 each
EUR 202.8

NADH, disodium salt

2735-500 each
EUR 170.4

NADH, disodium salt

2735-5000 each
EUR 652.8

NADP, disodium salt

2736-100 each
EUR 183.6

NADP, disodium salt

2736-1000 each
EUR 940.8

NADP, disodium salt

2736-500 each
EUR 548.4

NBQX disodium salt

2759-25 each
EUR 770.4

NBQX disodium salt

2759-5 each
EUR 248.4

BCA disodium salt

2810-100G each
EUR 1038

BCA disodium salt

2810-1G each
EUR 144

BCA disodium salt

2810-500G each
EUR 3126

BCA disodium salt

2810-5G each
EUR 261.6

EDTA calcium disodium salt dihydrate, BP, Ph. Eur., USP grade

GE8581-1KG 1 kg
EUR 241.2

EDTA calcium disodium salt dihydrate, BP, Ph. Eur., USP grade

GE8581-250G 250 g
EUR 103.2

EDTA calcium disodium salt dihydrate, BP, Ph. Eur., USP grade

GE8581-500G 500 g
EUR 151.2

1 Amp Conc EDTA (DiSodium salt) to make 1L 0.01M

EDC0011L EACH
EUR 28.5

1 Amp Conc EDTA (DiSodium salt) to make 1L 0.05M

ETC0051L EACH
EUR 28.5

ADA buffer, disodium salt

AB0005 25g
EUR 79.84

CL 316243 disodium salt

B6766-1 1 mg
EUR 130.8
Description: EC50: (3.0±0.3) X 10-8 M for ?3 adrenoceptor [1].Benzodioxole-containing phenethanolamine CL-316,243 is a murine-selective ?3 adrenoceptor agonist which can correct obesity and elevated blood glucose in diabetic rodents.

CL 316243 disodium salt

B6766-10 10 mg
EUR 351.6
Description: EC50: (3.0±0.3) X 10-8 M for ?3 adrenoceptor [1].Benzodioxole-containing phenethanolamine CL-316,243 is a murine-selective ?3 adrenoceptor agonist which can correct obesity and elevated blood glucose in diabetic rodents.

CL 316243 disodium salt

B6766-5 5 mg
EUR 247.2
Description: EC50: (3.0±0.3) X 10-8 M for ?3 adrenoceptor [1].Benzodioxole-containing phenethanolamine CL-316,243 is a murine-selective ?3 adrenoceptor agonist which can correct obesity and elevated blood glucose in diabetic rodents.

(RS)-MCPG disodium salt

B7476-10 10 mg
EUR 362.4

(RS)-MCPG disodium salt

B7476-50 50 mg
EUR 1336.8

Pamoic acid disodium salt

B7638-10 10 mg
EUR 576

Pamoic acid disodium salt

B7638-50 50 mg
EUR 2233.2

MUP, disodium salt, trihydrate

M0740 1g
EUR 112.2

Pamoic acid disodium salt

GK6564-100G 100 g
EUR 103.2

Pamoic acid disodium salt

GK6564-250G 250 g
EUR 170.4

Pamoic acid disodium salt

GK6564-25G 25 g
EUR 64.8

Sulfobromophthalein disodium salt hydrate

GK6995-25G 25 g
EUR 294

Sulfobromophthalein disodium salt hydrate

GK6995-5G 5 g
EUR 132

Clodronate disodium salt hydrate

GP6103-1G 1 g
EUR 103.2

UDP-GlcNAc Disodium Salt

HY-112174 5mg
EUR 198

Bathocuproinedisulfonic acid disodium salt

GT0734-100MG 100 mg
EUR 60

Bathocuproinedisulfonic acid disodium salt

GT0734-1G 1 g
EUR 132

Bathocuproinedisulfonic acid disodium salt

GT0734-250MG 250 mg
EUR 74.4

Bathocuproinedisulfonic acid disodium salt

GT0734-500MG 500 mg
EUR 96

EDTA, tetrasodium salt dihydrate

EB0436 500g
EUR 105.94

EDTA, dipotassium salt, dihydrate

ED0075 250g
EUR 99.67

EDTA tripotassium salt dihydrate

GL1464-100G 100 g
EUR 73.2

EDTA tripotassium salt dihydrate

GL1464-250G 250 g
EUR 103.2

EDTA tripotassium salt dihydrate

GL1464-25G 25 g
EUR 52.8

EDTA tripotassium salt dihydrate

GL1464-500G 500 g
EUR 153.6

EDTA tetrasodium salt hydrate

GE3450-100G 100 g
EUR 49.2

EDTA tetrasodium salt hydrate

GE3450-1KG 1 kg
EUR 81.6

EDTA tetrasodium salt hydrate

GE3450-250G 250 g
EUR 54

EDTA tetrasodium salt hydrate

GE3450-500G 500 g
EUR 63.6

EDTA tetrasodium salt hydrate

GE3450-5KG 5 kg
EUR 199.2

EDTA dipotassium salt dihydrate

GE5635-100G 100 g
EUR 64.8

EDTA dipotassium salt dihydrate

GE5635-250G 250 g
EUR 88.8

EDTA dipotassium salt dihydrate

GE5635-500G 500 g
EUR 122.4

EDTA ferric sodium salt

GE7700-100G 100 g
EUR 52.8

EDTA ferric sodium salt

GE7700-1KG 1 kg
EUR 117.6

EDTA ferric sodium salt

GE7700-250G 250 g
EUR 64.8

EDTA ferric sodium salt

GE7700-500G 500 g
EUR 84

EDTA trisodium salt dihydrate

GE9701-100G 100 g
EUR 64.8

EDTA trisodium salt dihydrate

GE9701-250G 250 g
EUR 93.6

EDTA trisodium salt dihydrate

GE9701-500G 500 g
EUR 141.6

EDTA tetrasodium salt dihydrate

GK0795-100G 100 g
EUR 48

EDTA tetrasodium salt dihydrate

GK0795-1KG 1 kg
EUR 84

EDTA tetrasodium salt dihydrate

GK0795-2500G 2500 g
EUR 141.6

EDTA tetrasodium salt dihydrate

GK0795-250G 250 g
EUR 55.2

EDTA tetrasodium salt dihydrate

GK0795-500G 500 g
EUR 63.6

MUP, disodium salt [4-Methylumbelliferyl phosphate, disodium salt] *CAS 22919-26-2*

11610 25 mg
EUR 138

MUP, disodium salt [4-Methylumbelliferyl phosphate, disodium salt] *CAS 22919-26-2*

11612 10 g
EUR 1077.6

DL-?-Hydroxyglutaric acid disodium salt

A3837-100 100 mg
EUR 223.2
Description: IC50: N/AD-?-Hydroxyglutaric acid, an ?-hydroxy acid formed from the hydrolysis of (R)-5-oxo-2-tetrahydrofurancarboxylic acid, is over-produced in the human neurometabolic disease D-?-hydroxyglutaric aciduria.

DL-?-Hydroxyglutaric acid disodium salt

A3837-25 25 mg
EUR 141.6
Description: IC50: N/AD-?-Hydroxyglutaric acid, an ?-hydroxy acid formed from the hydrolysis of (R)-5-oxo-2-tetrahydrofurancarboxylic acid, is over-produced in the human neurometabolic disease D-?-hydroxyglutaric aciduria.

DL-?-Hydroxyglutaric acid disodium salt

A3837-50 50 mg
EUR 184.8
Description: IC50: N/AD-?-Hydroxyglutaric acid, an ?-hydroxy acid formed from the hydrolysis of (R)-5-oxo-2-tetrahydrofurancarboxylic acid, is over-produced in the human neurometabolic disease D-?-hydroxyglutaric aciduria.

Guanosine 5'-triphosphate disodium salt

20-abx180774
  • EUR 360.00
  • EUR 678.00
  • 1 g
  • 5 g

Chromotropic Acid Disodium Salt Dihydrate

20-abx186412
  • EUR 393.60
  • EUR 276.00
  • 100 g
  • 25 g

BCA (Bicinchoninic acid), disodium salt

BB0260 5g
EUR 185.28

Creatine phosphate, disodium salt, Tetrahydrate

CB0128 5g
EUR 85.06

NADH disodium salt, trihydrate, reduced

NB0642 1g
EUR 98.63

Bicinchoninic acid disodium salt hydrate

GK3616-10G 10 g
EUR 160.8

Bicinchoninic acid disodium salt hydrate

GK3616-1G 1 g
EUR 64.8

Bicinchoninic acid disodium salt hydrate

GK3616-25G 25 g
EUR 288

Bicinchoninic acid disodium salt hydrate

GK3616-5G 5 g
EUR 108

Succinic acid disodium salt, anhydrous

GK7702-100G 100 g
EUR 51.6

Succinic acid disodium salt, anhydrous

GK7702-1KG 1 kg
EUR 112.8

Succinic acid disodium salt, anhydrous

GK7702-250G 250 g
EUR 62.4

Succinic acid disodium salt, anhydrous

GK7702-500G 500 g
EUR 79.2

Succinic acid disodium salt, anhydrous

GK7702-5KG 5 kg
EUR 294

Dexamethasone 21-phosphate disodium salt

GL6086-1G 1 g
EUR 132

Dexamethasone 21-phosphate disodium salt

GL6086-5G 5 g
EUR 322.8

Xanthosine 5'-monophosphate disodium salt

GN2077-100MG 100 mg
EUR 274.8

Xanthosine 5'-monophosphate disodium salt

GN2077-25MG 25 mg
EUR 112.8

Adenosine 5'-monophosphate disodium salt

GN7778-10G 10 g
EUR 98.4

Adenosine 5'-monophosphate disodium salt

GN7778-1G 1 g
EUR 60

Adenosine 5'-monophosphate disodium salt

GN7778-25G 25 g
EUR 151.2

Adenosine 5'-monophosphate disodium salt

GN7778-5G 5 g
EUR 74.4

Ceftriaxone disodium salt hemi(heptahydrate)

GA6812-1G 1 g
EUR 74.4

Ceftriaxone disodium salt hemi(heptahydrate)

GA6812-25G 25 g
EUR 274.8

Moreover, yokukansankachimpihange (YKH), a mix of yokukansan with Chimpi and Hange (Pinellia) was additionally examined as a result of Chimpi is taken into account to play an important half in this formulation in opposition to anxious signs in dementia sufferers.

The outcomes confirmed that Chimpi and YKH possess a major anxiolytic-like impact much like that of fluoxetine, suggesting that they could be much like fluoxetine in their pharmacological actions by way of the serotonergic neurotransmission pathway.

Moreover, it additionally advised that the main chemical constituent, hesperidin may very well be an lively precept attributed to the antianxiety-like results with a direct and oblique position through its aglycone hesperetin.